Tag: Heart / Stroke-Related: High Cholesterol
Evinacumab Cuts LDL-C Level in Familial Hypercholesterolemia
LDL-C down at week 24 with evinacumab versus placebo in homozygous familial hypercholesterolemia
Pitavastatin Effective for Lowering Lipids
Review shows it is more powerful for LDL cholesterol lowering than atorvastatin, rosuvastatin, and fluvastatin
Evolocumab Does Not Impact Cognition in Atherosclerotic CVD
Adding evolocumab to maximally tolerated statin therapy did not affect patient-reported cognition
2015 to 2018 Saw High Total Cholesterol for 11.4 Percent of U.S. Adults
Highest prevalence of high total cholesterol in those aged 40 to 59; prevalence similar by race/ethnicity
Public Policy Recs Updated for Familial Hypercholesterolemia
Goals include enhancing awareness of familial hypercholesterolemia as a global public health issue
APO(a)-LRX Found to Reduce Lipoprotein(a) Levels
Dose-dependent reduction found in patients with elevated lipoprotein(a) levels, cardiovascular disease
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk
Fifty percent reduction in non-HDLC concentration linked to reduced risk for CVD event by age 75 years
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk
Fifty percent reduction in non-HDLC concentration linked to reduced risk for CVD event by age 75 years
AHA: Lower-Target LDL Level Beneficial After Stroke, TIA
Subsequent risk for CV events lower among patients with ischemic stroke, TIA, evidence of atherosclerosis
AHA: Predictors for Meeting LDL-C, SBP Goals ID’d in ISCHEMIA
Older age, male sex, high-intensity statin use, lower baseline LDL-C predict LDL-C goal attainment
